Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Fentanyl 13Zoledronic Acid 8Ibandronic Acid 8nabiximols 6Oxycodone 6Tapentadol 5Morphine 4Hydromorphone 4Cryotherapy 4Cryosurgery 4alvimopan 3trimebutine 3-thiocarbamoylbenzenesulfonate 2resiniferatoxin 2cabozantinib 2Tetrodotoxin 2Radiation 2Prednisone 2Naloxone 2Diclofenac 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2ziconotide 1oxycodone naloxone combination 1imisopasem manganese 1fulranumab 1Xylitol 1Ultracet 1Transdermal Patch 1Therapeutics 1Sufentanil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pain × Ultracet × Clear all
NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡